Cargando…
Topical Ocular Delivery of TGF-β1 to the Back of the Eye: Implications in Age-Related Neurodegenerative Diseases
Dysregulation of the transforming growth factor-β1 (TGF-β1)/selected small mother against decapentaplegic (SMAD) pathway can be implicated in development of age-related macular degeneration (AMD), and the delivery of TGF-β1 could be beneficial for AMD. We developed a new ophthalmic formulation of TG...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666758/ https://www.ncbi.nlm.nih.gov/pubmed/28973964 http://dx.doi.org/10.3390/ijms18102076 |
_version_ | 1783275365863522304 |
---|---|
author | Platania, Chiara Bianca Maria Fisichella, Vincenzo Fidilio, Annamaria Geraci, Federica Lazzara, Francesca Leggio, Gian Marco Salomone, Salvatore Drago, Filippo Pignatello, Rosario Caraci, Filippo Bucolo, Claudio |
author_facet | Platania, Chiara Bianca Maria Fisichella, Vincenzo Fidilio, Annamaria Geraci, Federica Lazzara, Francesca Leggio, Gian Marco Salomone, Salvatore Drago, Filippo Pignatello, Rosario Caraci, Filippo Bucolo, Claudio |
author_sort | Platania, Chiara Bianca Maria |
collection | PubMed |
description | Dysregulation of the transforming growth factor-β1 (TGF-β1)/selected small mother against decapentaplegic (SMAD) pathway can be implicated in development of age-related macular degeneration (AMD), and the delivery of TGF-β1 could be beneficial for AMD. We developed a new ophthalmic formulation of TGF-β1 assessing the ocular pharmacokinetic profile of TGF-β1 in the rabbit eye. Small unilamellar vesicles (SUV) loaded with TGF-β1 were complemented with Annexin V and Ca(2+), and the vitreous bioavailability of TGF-β1 was assessed after topical ocular administration by a commercial ELISA kit. We detected high levels of TGF-β1 (C(max) 114.7 ± 12.40 pg/mL) in the vitreous after 60 min (T(max)) from the topical application of the liposomal suspension. Ocular tolerability was also assessed by a modified Draize’s test. The new formulation was well tolerated. In conclusion, we demonstrated that the novel formulation was able to deliver remarkable levels of TGF-β1 into the back of the eye after topical administration. Indeed, this TGF-β1 delivery system may be useful in clinical practice to manage ophthalmic conditions such as age-related macular degeneration, skipping invasive intraocular injections. |
format | Online Article Text |
id | pubmed-5666758 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-56667582017-11-09 Topical Ocular Delivery of TGF-β1 to the Back of the Eye: Implications in Age-Related Neurodegenerative Diseases Platania, Chiara Bianca Maria Fisichella, Vincenzo Fidilio, Annamaria Geraci, Federica Lazzara, Francesca Leggio, Gian Marco Salomone, Salvatore Drago, Filippo Pignatello, Rosario Caraci, Filippo Bucolo, Claudio Int J Mol Sci Communication Dysregulation of the transforming growth factor-β1 (TGF-β1)/selected small mother against decapentaplegic (SMAD) pathway can be implicated in development of age-related macular degeneration (AMD), and the delivery of TGF-β1 could be beneficial for AMD. We developed a new ophthalmic formulation of TGF-β1 assessing the ocular pharmacokinetic profile of TGF-β1 in the rabbit eye. Small unilamellar vesicles (SUV) loaded with TGF-β1 were complemented with Annexin V and Ca(2+), and the vitreous bioavailability of TGF-β1 was assessed after topical ocular administration by a commercial ELISA kit. We detected high levels of TGF-β1 (C(max) 114.7 ± 12.40 pg/mL) in the vitreous after 60 min (T(max)) from the topical application of the liposomal suspension. Ocular tolerability was also assessed by a modified Draize’s test. The new formulation was well tolerated. In conclusion, we demonstrated that the novel formulation was able to deliver remarkable levels of TGF-β1 into the back of the eye after topical administration. Indeed, this TGF-β1 delivery system may be useful in clinical practice to manage ophthalmic conditions such as age-related macular degeneration, skipping invasive intraocular injections. MDPI 2017-09-30 /pmc/articles/PMC5666758/ /pubmed/28973964 http://dx.doi.org/10.3390/ijms18102076 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Platania, Chiara Bianca Maria Fisichella, Vincenzo Fidilio, Annamaria Geraci, Federica Lazzara, Francesca Leggio, Gian Marco Salomone, Salvatore Drago, Filippo Pignatello, Rosario Caraci, Filippo Bucolo, Claudio Topical Ocular Delivery of TGF-β1 to the Back of the Eye: Implications in Age-Related Neurodegenerative Diseases |
title | Topical Ocular Delivery of TGF-β1 to the Back of the Eye: Implications in Age-Related Neurodegenerative Diseases |
title_full | Topical Ocular Delivery of TGF-β1 to the Back of the Eye: Implications in Age-Related Neurodegenerative Diseases |
title_fullStr | Topical Ocular Delivery of TGF-β1 to the Back of the Eye: Implications in Age-Related Neurodegenerative Diseases |
title_full_unstemmed | Topical Ocular Delivery of TGF-β1 to the Back of the Eye: Implications in Age-Related Neurodegenerative Diseases |
title_short | Topical Ocular Delivery of TGF-β1 to the Back of the Eye: Implications in Age-Related Neurodegenerative Diseases |
title_sort | topical ocular delivery of tgf-β1 to the back of the eye: implications in age-related neurodegenerative diseases |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666758/ https://www.ncbi.nlm.nih.gov/pubmed/28973964 http://dx.doi.org/10.3390/ijms18102076 |
work_keys_str_mv | AT plataniachiarabiancamaria topicaloculardeliveryoftgfb1tothebackoftheeyeimplicationsinagerelatedneurodegenerativediseases AT fisichellavincenzo topicaloculardeliveryoftgfb1tothebackoftheeyeimplicationsinagerelatedneurodegenerativediseases AT fidilioannamaria topicaloculardeliveryoftgfb1tothebackoftheeyeimplicationsinagerelatedneurodegenerativediseases AT geracifederica topicaloculardeliveryoftgfb1tothebackoftheeyeimplicationsinagerelatedneurodegenerativediseases AT lazzarafrancesca topicaloculardeliveryoftgfb1tothebackoftheeyeimplicationsinagerelatedneurodegenerativediseases AT leggiogianmarco topicaloculardeliveryoftgfb1tothebackoftheeyeimplicationsinagerelatedneurodegenerativediseases AT salomonesalvatore topicaloculardeliveryoftgfb1tothebackoftheeyeimplicationsinagerelatedneurodegenerativediseases AT dragofilippo topicaloculardeliveryoftgfb1tothebackoftheeyeimplicationsinagerelatedneurodegenerativediseases AT pignatellorosario topicaloculardeliveryoftgfb1tothebackoftheeyeimplicationsinagerelatedneurodegenerativediseases AT caracifilippo topicaloculardeliveryoftgfb1tothebackoftheeyeimplicationsinagerelatedneurodegenerativediseases AT bucoloclaudio topicaloculardeliveryoftgfb1tothebackoftheeyeimplicationsinagerelatedneurodegenerativediseases |